ABL kinase Inhibitors
2 drugsAbout ABL kinase
ABL kinase, also known as Abelson tyrosine kinase, is a non-receptor tyrosine kinase involved in cell growth, differentiation, and survival. It plays a crucial role in signal transduction pathways.
ABL kinase is a therapeutic target in oncology, though there is currently no genetic evidence linking it to specific diseases. Its role in cancer-related pathways makes it a valuable target.
ABL kinase is targeted by two FDA-approved small molecule drugs, PHYRAGO and SPRYCEL, both used in oncology. These drugs demonstrate the feasibility of modulating ABL kinase activity for therapeutic benefit.
Top ABL kinase Drugs
The ABL kinase drug market is concentrated with HANDA THERAP and Bristol-Myers Squibb.
High concentration suggests significant barriers to entry for new companies.
ABL kinase Drug Modality Landscape
Modalities
Routes of Administration
ABL kinase is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies could provide a competitive advantage.
ABL kinase Clinical Trials 218 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ABL kinase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 89 | 45 | 31 | 13 | 59% |
| Phase 2 | 112 | 49 | 26 | 36 | 65% |
| Phase 3 | 11 | 6 | 1 | 4 | 86% |
| Phase 4 | 6 | 2 | 0 | 4 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ABL kinase Drug Approval Timeline (2006 - 2023)
The first ABL kinase drug was approved in 2006, with the most recent in 2023.
The approval timeline indicates continued interest and potential in targeting ABL kinase.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 111 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ABL kinase. A trial counts if an approved drug acting on ABL kinase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.